Sarepta Therapeutics Reports Q4 & Full-Year 2025 Results, Highlights Positive ELEVIDYS Data & Pipeline Progress

summarizeSummary

Sarepta Therapeutics reported a GAAP net loss for Q4 and full-year 2025, impacted by a regulatory label update for ELEVIDYS and R&D investments, but highlighted positive 3-year ELEVIDYS clinical data, Japan launch, and pipeline advancements.

check_boxKey Events

• Reports Q4 & Full-Year 2025 Financials

  Sarepta reported full-year 2025 total revenues of $2.2 billion (+16% YoY) but a GAAP net loss of $713.4 million. Q4 2025 revenues were $442.9 million (-33% YoY) with a GAAP net loss of $412.2 million.

• Positive 3-Year ELEVIDYS EMBARK Data

  The company announced positive three-year results from the Phase 3 EMBARK study for ELEVIDYS, showing clinically meaningful, statistically significant, and durable benefits in motor function for Duchenne muscular dystrophy patients.

• ELEVIDYS Launched in Japan

  ELEVIDYS Intravenous Infusion was launched in Japan in February 2026, following May 2025 approval, triggering a $40 million milestone payment.

• Pipeline Advancement for Huntington's Disease

  Sarepta received approval to begin a Phase 1 trial for SRP-1005, an siRNA therapeutic for Huntington's disease, in Q2 2026.

auto_awesomeAnalysis

Sarepta Therapeutics reported a significant GAAP net loss for both Q4 and full-year 2025, primarily driven by increased R&D expenses related to Arrowhead milestones and a substantial decrease in ELEVIDYS net product revenue in Q4. This revenue decline was a direct consequence of the November 2025 FDA label update, which added a boxed warning for liver injury and removed the non-ambulatory indication for ELEVIDYS. Despite these financial challenges, the company highlighted strong positive three-year clinical data from the EMBARK study for ELEVIDYS, demonstrating durable benefits in motor function. Additionally, Sarepta announced the launch of ELEVIDYS in Japan, pipeline advancements for Huntington's disease, and strategic financial moves including debt refinancing and a restructuring plan aimed at achieving profitability and positive cash flow in 2026. Investors should weigh the current financial losses and regulatory setback against the strong clinical data, pipeline progress, and strategic efforts to improve financial stability and expand market access.